'No Meaningful Change' In Pricing Environment, Teva Says
Executive Summary
Teva reported a drop in first quarter revenues that was smaller than expected on better sales from its specialty business. CEO Erez Vigodman claims the deal to acquire Allergan's generics business is on track to close in June and will transform Teva into an "even stronger company."
You may also be interested in...
FTC Review Ongoing As Teva/Allergan Await Final Approval
Analysts had been expecting Teva's acquisition of Allergan's generics business to close at the end of June; Teva insists the acquisition is still going to plan.
Dr Reddy's Pumps Complex Generics Play with Teva deal
Dr. Reddy's Laboratories Ltd. is acquiring a basket of ANDAs from Teva Pharmaceutical Industries Ltd. as it increasingly leans towards developing and building a portfolio of complex and limited competition generics in the US and hopes to become "more relevant" there.
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.